Page last updated: 2024-11-11

ym 758

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

YM 758: an If channel inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71753007
MeSH IDM0523126

Synonyms (1)

Synonym
ym 758

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The drug-drug interaction (DDI) potential of these drugs for the hOCT/rOct-mediated hepatic/renal uptake process was also assessed."( Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions.
Iwatsubo, T; Kamimura, H; Noguchi, K; Umehara, KI; Usui, T, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" YM758 was well absorbed from all segments of the gastrointestinal tract except for the stomach."( Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats.
Kamimura, H; Nakamura, E; Noguchi, K; Seya, K; Sonoda, T; Umehara, KI; Usui, T, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The recovery rates of radioactivity in urine and bile after oral dosing to bile duct-cannulated albino rats were 17."( Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats.
Kamimura, H; Nakamura, E; Noguchi, K; Seya, K; Sonoda, T; Umehara, KI; Usui, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (87.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]